- Report
- May 2024
- 50 Pages
Global
From €2555EUR$2,650USD£2,185GBP
- Report
- March 2024
- 257 Pages
Global
From €7231EUR$7,500USD£6,184GBP
- Report
- January 2022
- 117 Pages
Global
From €4579EUR$4,750USD£3,917GBP
- Report
- May 2021
- 50 Pages
China
From €2507EUR$2,600USD£2,144GBP
- Report
- July 2018
- 30 Pages
China
From €2121EUR$2,200USD£1,814GBP
- Report
- December 2021
- 141 Pages
Global
From €10600EUR$10,995USD£9,066GBP
- Report
- November 2023
- 290 Pages
China
From €3856EUR$4,000USD£3,298GBP
- Report
- July 2020
- 1740 Pages
Global
From €4628EUR$4,800USD£3,958GBP
- Report
- July 2018
- 175 Pages
Global
From €21210EUR$22,000USD£18,140GBP
- Report
- February 2024
- 85 Pages
Global
From €3500EUR$3,889USD£3,098GBP
- Report
- November 2023
- 145 Pages
China
From €1735EUR$1,800USD£1,484GBP
Imatinib is a drug used to treat certain types of leukemia, a cancer of the blood and bone marrow. It is a tyrosine kinase inhibitor, meaning it works by blocking the action of certain enzymes that are involved in the growth and spread of cancer cells. Imatinib is used to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). It is also used to treat certain types of gastrointestinal stromal tumors (GISTs). Imatinib is available in both generic and brand-name forms.
Imatinib is a widely used drug in the treatment of leukemia, and is often prescribed as a first-line treatment for CML and GISTs. It is generally well-tolerated and has been shown to be effective in controlling the disease and prolonging survival.
Some companies in the Imatinib market include Novartis, Pfizer, and Cipla. Show Less Read more
